Skip to main content
Ocugen, Inc. logo

Ocugen, Inc. — Investor Relations & Filings

Ticker · OCGN ISIN · US43358V1098 LEI · 549300JVNUI9CXWJLR09 US Manufacturing
Open in API
Filings indexed 849 across all filing types
Latest filing 2018-05-18 Director's Dealing
Country US United States of America
Listing US OCGN

About Ocugen, Inc.

https://ocugen.com/

Ocugen, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel gene therapies, cell therapies, and vaccines. The company's primary mission is to develop treatments for blindness diseases, leveraging its first-in-class modifier gene therapy platform. This platform represents a potential paradigm shift in treating inherited retinal diseases by aiming to address multiple genetic mutations with a single product. In addition to its focus on ocular health, Ocugen is also advancing a pipeline that includes vaccines for infectious diseases. The company is dedicated to addressing significant unmet medical needs and providing innovative therapeutic options for patients with debilitating conditions.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2018-05-18 English
10-Q
Interim / Quarterly Report Q1 2018
2018-05-10 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 10, 2018, by Histogenics Corporation. It reports the issuance of a press release and a conference call regarding the company's results of operations and financial condition for the quarter ended March 31, 2018. The document references a press release as Exhibit 99.1 and mentions a conference call but does not contain detailed financial statements or substantive financial data itself. The content is typical of an initial announcement of quarterly financial results, which aligns with an Earnings Release. The document length (6805 characters) and content indicate it is not the full quarterly report but an announcement of results and a conference call. Therefore, the appropriate classification is Earnings Release (ER).
2018-05-10 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or additional materials related to a shareholder meeting. It includes information about the annual meeting, voting instructions, election of directors, and ratification of the independent auditor. It is not the proxy statement itself but additional materials related to the proxy solicitation process. The document is not a full annual report, earnings release, or management report. It is specifically related to proxy solicitation and voting information for shareholders. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI). The document length (6407 characters) and content confirm it is not merely an announcement but actual proxy materials or additional proxy materials.
2018-04-26 English
DEF 14A
Proxy Solicitation & Information Statement
2018-04-26 English
FORM 4 SUBMISSION
Director's Dealing
2018-04-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.